secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-088950
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024
--------------------------------------------------------------------------------

- Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.
- Cash $123.6M; expected runway into H2 2026.
- PBGENE-HBV on track for IND/CTA submission in 2024; PBGENE-PMM targeted for 2025.
- Regained control of three preclinical programs from Prevail (DMD, liver, CNS) for internal/partner development.
- Entered into $22.5M term loan with Banc of California (maturity June 2027).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/0000950170-24-088950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/dtil-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer